-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SPL-028 in Generalized Anxiety Disorder (GAD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SPL-028 in Generalized Anxiety Disorder (GAD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SPL-028 in Generalized Anxiety Disorder (GAD) Drug Details: SPL-028 is...
-
Product Insights
NewGeneralized Anxiety Disorder (GAD) – Drugs In Development, 2024
Empower your strategies with our Generalized Anxiety Disorder (GAD) – Drugs In Development, 2024 report and make more profitable business decisions. Generalized anxiety disorder is a mental health disorder that produces fear, worry, and a constant feeling of being overwhelmed. It is characterized by excessive, persistent, and unrealistic worry about everyday things. Individuals with GAD typically experience heightened anxiety and apprehension, anticipating negative outcomes in everyday situations. Physical symptoms may include restlessness, muscle tension, fatigue, and difficulty concentrating. Unlike specific phobias...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ABBV-932 in Schizophrenia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ABBV-932 in Schizophrenia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ABBV-932 in Schizophrenia Drug Details: ABBV-932 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ABBV-932 in Bipolar Disorder (Manic Depression)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ABBV-932 in Bipolar Disorder (Manic Depression) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ABBV-932 in Bipolar Disorder (Manic Depression) Drug Details: ABBV-932...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Diamyd in Type 1 Diabetes (Juvenile Diabetes)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Diamyd in Type 1 Diabetes (Juvenile Diabetes) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Diamyd in Type 1 Diabetes (Juvenile Diabetes) Drug...
-
Product Insights
NewNet Present Value Model: Merck & Co Inc’s Nemtabrutinib
Empower your strategies with our Net Present Value Model: Merck & Co Inc's Nemtabrutinib report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ABBV-932 in Generalized Anxiety Disorder (GAD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ABBV-932 in Generalized Anxiety Disorder (GAD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ABBV-932 in Generalized Anxiety Disorder (GAD) Drug Details: ABBV-932 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PT-00114 in Generalized Anxiety Disorder (GAD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PT-00114 in Generalized Anxiety Disorder (GAD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PT-00114 in Generalized Anxiety Disorder (GAD) Drug Details: PT-00114 (TCAP-1)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Personalized Neoantigen Tumor Vaccine in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Personalized Neoantigen Tumor Vaccine in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Personalized Neoantigen Tumor Vaccine in Solid Tumor Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ulotaront Hydrochloride in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ulotaront Hydrochloride in Parkinson's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ulotaront Hydrochloride in Parkinson's Disease Drug Details: Ulotaront hydrochloride (SEP-363856, SEP-856)...